The expanded Access Program provides a pathway for patients to gain access to treatment with ExoFlo outside of the active Phase II research clinical trial. Direct Biologics, announced today that the first patient has been treated under its expanded access ...
Read More »Direct Biologics Announces the Launch of ExoFlo Exosomes
Direct Biologics, LLC announces the launch of ExoFloTM Exosomes. The mission of Direct Biologics is to deliver disruptive and innovative products that unlock the healing potential within a patient’s own...
Read More »